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high-resolution Ultrasonography of 
the superficial Peroneal Motor and 
sural sensory nerves May Be a  
non-invasive approach to the 
Diagnosis of Vasculitic neuropathy
Nurcan Üçeyler* , Kristina A. Schäfer , Daniel Mackenrodt , Claudia Sommer and  
Wolfgang Müllges
Department of Neurology, University of Würzburg, Würzburg, Germany
High-resolution ultrasonography (HRUS) is an emerging new tool in the investigation of 
peripheral nerves. We set out to assess the utility of HRUS performed at lower extremity 
nerves in peripheral neuropathies. Nerves of 26 patients with polyneuropathies of different 
etiologies and 26 controls were investigated using HRUS. Patients underwent clinical, 
laboratory, electrophysiological assessment, and a diagnostic sural nerve biopsy as part 
of the routine work-up. HRUS was performed at the sural, tibial, and the common, super-
ficial, and deep peroneal nerves. The superficial peroneal nerve longitudinal diameter (LD) 
distinguished best between the groups: patients with immune-mediated neuropathies 
(n = 13, including six with histology-proven vasculitic neuropathy) had larger LD com-
pared to patients with non-immune-mediated neuropathies (p < 0.05) and to controls 
(p < 0.001). Among all subgroups, patients with vasculitic neuropathy showed the largest 
superficial peroneal nerve LD (p < 0.001) and had a larger sural nerve cross-sectional 
area when compared with disease controls (p < 0.001). Enlargement of the superficial 
peroneal and sural nerves as detected by HRUS may be a useful additional finding in the 
differential diagnosis of vasculitic and other immune-mediated neuropathies.
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inTrODUcTiOn
Diagnosing potentially treatable immune-mediated neuropathies can be challenging, particularly, in 
vasculitic neuropathy, which is one of the most severe, but treatable forms (1). Vasculitic neuropathy 
can either be part of a systemic vasculitis or can present as non-systemic vasculitic neuropathy 
(NSVN) with single organ involvement of the peripheral nervous system (2, 3). Nerve biopsy is 
the gold standard to prove vasculitic neuropathy (4); however, its sensitivity reaches only 20–60% 
(1, 4–7). Furthermore, nerve biopsy is invasive, there may be contraindications such as conditions 
leading to impaired wound healing and potential long-term side effects such as dysesthesias and pain 
in the biopsy area. Therefore, a non-invasive technique for peripheral nerve assessment is warranted.
High-resolution ultrasonography (HRUS) is a non-invasive technique that is increasingly used 
in the diagnostic work-up of peripheral neuropathies. Examples of frequently investigated disorders 
are entrapment syndromes (8), hereditary neuropathies (9), or diabetic neuropathy (10). Recently, 
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also immune-mediated neuropathies have been studied with 
HURS. Arm nerves are easier to access by HURS (11) but are 
often less affected in immune-mediated neuropathies, such 
that sonography of lower limb nerves is increasingly performed 
(12–14). We prospectively studied the utility of HRUS by assess-
ing lower extremity nerves in patients with immune-mediated 
and non-immune-mediated neuropathies of different etiologies.
PaTienTs anD MeThODs
case ascertainment and study cohort
Our study was approved by the Würzburg Medical Faculty Ethics 
Committee (#165/10). All patients gave written informed consent 
before study inclusion. From November 2010 to July 2012, we 
prospectively recruited Caucasian patients with neuropathies of 
different etiologies who came to our Department of Neurology, 
University of Würzburg, for diagnostic work-up. Patients under-
went thorough neurological examination, extensive laboratory 
tests including cerebrospinal fluid analysis, and electrophysiol-
ogy was performed adapting to their individual symptoms and 
signs. Only patients who also underwent sural nerve biopsy for 
diagnostic reasons were included in our study. Further inclusion 
criteria were ≥18 years, body height of 160–180 cm. Age- and 
gender-matched Caucasian disease controls consisted of patients 
with neurological disorders other than peripheral neuropathies 
seen at our department for diagnostic and/or therapeutic reasons 
(e.g., myasthenia gravis, Parkinson’s disease, and transitory 
ischemic attack). In these patients, peripheral neuropathy was 
excluded by history and clinical examination; thus, patients with 
ataxia, distal symmetric hypoesthesia, or peripheral pareses were 
excluded. Ankle reflexes and vibration sense of at least seven 
out of eight at the toes were prerequisites for study inclusion of 
controls. Age was matched with the patient group at a difference 
of 5  years at a maximum. The following diagnostic subgroups 
were distinguished.
Chronic Inflammatory Demyelinating Neuropathy
Patients were diagnosed as chronic inflammatory demyelinat-
ing neuropathy (CIDP) when the INCAT criteria were fulfilled 
(inflammatory neuropathy cause and treatment) (15).
CIDPclin
These patients had the typical clinical presentation and laboratory 
findings and showed a demyelinating neuropathy in neurophysi-
ological and histological assessment, which is the characteristic 
for CIDP, but did not fulfill the neurophysiological INCAT 
criteria.
CIDPsens
These patients had purely sensory symptoms with a duration of 
≥2 months, signs of demyelination in neurophysiological assess-
ment, signs of demyelination and inflammation in the sural nerve 
biopsy, elevated cerebrospinal fluid protein, a positive response 
on steroid treatment, and normal to slightly reduced intraepider-
mal nerve fiber density in the skin punch biopsy taken from the 
distal lateral thigh during sural nerve biopsy (see below) (16, 17).
Vasculitic Neuropathy
These patients were divided in those with systemic vasculitis and 
those with NSVN (4).
Chronic Idiopathic Axonal Polyneuropathy
These patients reported slow disease onset with slow progression. 
Clinical presentation was sensory-motor and neurophysiology 
revealed axonal neuropathy. Histology was axonal but without 
signs of inflammation. Cerebrospinal fluid was normal and 
intraepidermal nerve fiber density was reduced. Steroid treat-
ment was inefficacious (18).
Unknown Etiology
In this group, we summarized all cases in which a definitive 
diagnosis as detailed above was not possible at the time point of 
study inclusion.
In some cases, neuropathy turned out to be associated with 
amyotrophic lateral sclerosis (ALS), later, which was diagnosed 
according to the revised El-Escorial criteria (19). One patient had 
adrenomyeloneuroropathy.
DiagnOsTic analYses
laboratory Tests
The following laboratory tests were performed in all patients: 
whole blood and differential cell counts, chemistry panel, 
erythrocyte sedimentation rate, C-reactive protein, antinuclear 
antibodies (ANA), antibodies against extractable nuclear antigen, 
ENA, antineutrophil cytoplasmic autoantibody (ANCA), rheu-
matoid factor, HCV antibodies, HBV surface antigen, Borrelia 
antibodies, serum ACE, and in selected cases with abnormalities 
on immunofixation or immunoelectrophoresis we searched for 
cryoglobulins. Other causes of neuropathies had been excluded 
with regard to the individual history and presentation by appro-
priate laboratory tests (e.g., HbA1c, oral glucose tolerance test, 
serum electrolytes, immunofixation for monoclonal gammopa-
thy, vitamin B12 levels, and creatine kinase). All patients had 
undergone diagnostic lumbar puncture, either at our department 
or in a hospital prior to admission with most of the data avail-
able to us. The cerebrospinal fluid was examined for glucose, cell 
count, protein levels, and oligoclonal bands.
neurophysiological assessment
Neurophysiological assessment was done in all patients following 
standard procedures (20), including nerve conduction studies 
of motor and sensory nerves at the lower and upper limbs in 
combination with needle electromyography in weak muscles. Of 
all electrophysiological tests performed during routine patient 
assessment, we only used the results of conduction studies of the 
sural nerve that was later biopsied and of the tibial nerve (anti-
dromic recording; surface electrodes) for the present analyses. 
This was due to the heterogeneity of the data obtained during 
individual patient assessment. Results were compared with the 
normal values of our department’s electroneurography unit: 
lower limit of normal for sural nerve sensory nerve action poten-
tial (SNAP) amplitude of 10 μV for patients ≤65  years of age, 
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FigUre 1 | The photographs in the upper row show the investigation sites of the reported peripheral nerves. In the middle row, an example for each 
nerve is given in the transverse sections and in the lower row in longitudinal sections. The nerves are marked with either cyan circles (transverse) or crosses 
(longitudinal).
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5 μV for >65 years of age; sural nerve conduction velocity (NCV) 
of 40 m/s for all adult ages; tibial nerve compound motor action 
potential (CMAP) of 10 mV, upper limit of distal motor latency 
(dmL) of 6.0 ms, and lower limit of NCV of 40 m/s for all adults. 
Motor nerve conduction block was assumed if tibial nerve CMAP 
on the proximal stimulus was below 50% of distal amplitude in 
the absence of significant dispersion (<30%). If skin temperature 
measured at distal calf level was <32°C, legs were warmed up to 
≥34°C by water immersion.
sural nerve Biopsy
Diagnostic sural nerve biopsy was performed under local skin 
and tissue anesthesia excluding the nerve (21) in those cases that 
were of sufficient severity and progression and where the etiology 
of neuropathy was unclear after clinical, laboratory, and neuro-
physiological assessment. Nerve specimens were processed for 
routine stains (hematoxylin–eosin for overview and nerve mor-
phology, elastica van Gieson for morphology of the vessel wall, 
and Congo red for amyloid) on paraffin sections, for semithin 
sections (azure-methylene blue), and for immunohistochemistry 
for T cells and macrophages (22).
high-resolution Ultrasonography
For HRUS of the peripheral nerves, the Aplio XG ultrasonography 
device with an 18 MHz linear transducer was used equipped with 
its standard Tissue Harmonic Imaging Software (Toshiba Medical 
Systems, Japan). All assessments were performed unilaterally in a 
standardized manner on transverse and longitudinal sections in 
sitting or prone position as appropriate. Device mode was kept 
the same for all assessments and the zoom function was not used 
during measurements (23). The investigator (Kristina A. Schäfer) 
was trained and supervised thoroughly by two experienced ultra-
sonographers (Wolfgang Müllges and Mira Schließer). All data 
were additionally cross-checked off-line (Wolfgang Müllges). 
HURS assessment was performed in a blinded manner as for the 
exact neuropathy diagnosis. The following nerves were examined 
and exact landmarks are illustrated in Figure 1:
 – sural nerve, 20 cm proximal lateral malleolus and at level of 
lateral malleolus,
 – tibial nerve, at level of medial malleolus,
 – common peroneal nerve, 5 cm below head of fibula,
 – deep peroneal nerve, 3 cm proximal of lateral malleolus and 
15 cm distal of lateral malleolus,
 – superficial peroneal nerve, 5 cm above lateral malleolus.
At each measurement point, the following parameters were 
determined (Figure 1):
 – largest transversal diameter (LTD) in millimeter (i.e., diameter 
upon sonography of the nerve in a transversal section),
 – smallest transversal diameter (STD) in millimeter (i.e., diam-
eter upon sonography of the nerve in a transverse section),
 – longitudinal diameter (LD) in millimeter (i.e., diameter upon 
sonography of the nerve in a longitudinal section),
 – transversal cross-sectional area (CSA) in square millimeter.
During all measurements, the probe angle was positioned 
perpendicular to the nerve. All measurements were performed 
manually within the hyperechoic nerve rim. Two measurements 
were recorded at each investigated site after reposition of the 
FigUre 2 | Box-and-whisker plots illustrate the enlarged median 
cross-sectional area (csa) in high-resolution ultrasonography (hrUs) 
of the sural nerves of patients with vasculitic neuropathy compared 
with disease controls (*p < 0.05).
TaBle 1 | Patients’ clinical characteristics and diagnostic subgroups.
item number (% of entire group)
M, F (N) 20, 6
Median age (range) 66 years (37–81)
Median disease duration (range in years) 2 years (0.06–30)
Diagnostic subgroups, N (% of entire group)
Unknown etiology 9 (35)
Vasculitic neuropathy 6 (23)
NSVN 4 (67)
ALS 3 (12)
CIDP 2 (8)
CIDPclin 2 (8)
CIDPsens 2 (8)
CIAP 1 (4)
Adrenomyeloneuoropathy 1 (4)
ALS, amyotrophic lateral sclerosis; CIAP, chronic idiopathic axonal polyneuropathy; 
CIDP, chronic inflammatory demyelinating polyneuropathy; CIDPclin, patients with a 
clinical presentation typical of CIDP, but not fulfilling electrophysiological INCAT criteria; 
CIDPsens, patients with pure sensory clinical presentation and otherwise like CIDP, 
but not fulfilling all electrophysiological INCAT criteria; F, females; INCAT, inflammatory 
neuropathy cause and treatment group; M, males; N, number; NSVN, non-systemic 
vasculitic neuropathy.
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probe and data were averaged. In patients, nerves were examined 
on the right side; the sural nerve that was later biopsied was 
always investigated. In control subjects, the side of examination 
was selected individually.
statistical analysis
For statistical analyses, IBM SPSS Version 23 was used (Ehningen, 
Germany). Data with normal distribution in the Shapiro–Wilk 
test were assessed using the parametric Student’s t-test and the 
Welch test; non-normally distributed data were evaluated with 
the non-parametric Mann–Whitney U-test. p-Value <0.05 was 
assumed as significant. Data are illustrated as box-and-whisker 
plots displaying the median, the upper 75% and lower 25% per-
centiles, and the minimum and maximum values.
resUlTs
Patient characteristics, clinical and 
laboratory Presentations
We included 26 consecutive patients with polyneuropathies of 
different etiologies (20 males and 6 females) and a median age of 
66 years (range 37–81 years). The median time between symptom 
onset and diagnostic evaluation at our department was 2 years 
(0.06–30 years). The age- and gender-matched group of disease 
controls consisted of 26 subjects (20 males and 6 females) with a 
median age of 70 years (range 39–84 years). Table 1 gives demo-
graphic data including diagnostic subgroups. For individual 
neurophysiological data, see Table S1 in Supplementary Material.
sural nerve histology
Histological assessment of the sural nerve showed evidence of vas-
culitic neuropathy in 6/26 (23%) patients in accordance with the 
published criteria (4). Among the remaining cases, non-vasculitic 
histological signs of inflammation contributed to the diagnoses 
of CIDP, CIDPclin, CIDPsens, and chronic idiopathic axonal 
polyneuropathy (CIAP) in 7/26 (27%) patients. These 13 cases 
were summarized as immune mediated and were compared with 
the remaining non-immune-mediated cases in further analyses, 
in addition to the separate analyses of the vasculitis cases.
Peripheral neuropathies are associated 
with lower extremity nerve enlargement
Table S2 in Supplementary Material summarizes the means and 
SDs of the obtained HRUS data. Almost all examined nerves 
and parameters showed higher values for the group of patients 
with neuropathies compared to controls (Tables  S2 and S3 in 
Supplementary Material). However, most of the determined 
parameters did not distinguish between immune-mediated 
and non-immune-mediated neuropathies (Tables  S2 and S3 in 
Supplementary Material). Particularly HRUS data of the later 
biopsied sural nerve were not different when comparing histo-
logically inflamed- and non-inflamed nerves. This was also true 
for the group of vasculitic neuropathy, which only showed larger 
sural nerve CSA when compared with disease controls (p < 0.05, 
Figure 2).
superficial Peroneal nerve hrUs lD is 
Most informative When comparing 
Diagnostic subgroups
The superficial peroneal nerve LD was the most informative 
parameter when comparing the entire group of neuropathy 
patients with controls. Median LD was larger in patients 
with neuropathies compared to disease controls (p  <  0.001, 
Figure 3A). The LD of the superficial peroneal nerve did not dif-
fer between patients with non-immune-mediated neuropathies 
and controls but was larger in patients with immune-mediated 
neuropathies compared to patients with non-immune-mediated 
neuropathies (p < 0.05) and controls (p < 0.001, Figure 3B). This 
was particularly the case in patients with vasculitic neuropathy 
(Figures 3C,D). See Video S1 in Supplementary Material for a 
demonstration of the measurement of the superficial peroneal 
nerve CSA and LD.
FigUre 3 | Box-and-whisker plots illustrate the results of high-resolution ultrasonography (hrUs) of the superficial peroneal nerve in patients with 
neuropathies and disease controls; the longitudinal diameter (lD) is displayed in millimeter. (a) Patients with peripheral neuropathies have larger LD of the 
superficial peroneal nerve than disease controls. (B) The subgroup of patients with immune-mediated neuropathies (“immune NP”) has increased LD when 
compared to disease controls and to patients with non-immune-mediated neuropathies. (c) When separating vasculitic neuropathy from the group of other 
immune-mediated neuropathies, LD was largest, and also, when comparing vasculitic neuropathy with all other non-vasculitic neuropathies (“non-immune NP”) 
(D). *p < 0.05, **p < 0.01, and ***p < 0.001.
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DiscUssiOn
We investigated lower extremity nerves of patients with immune-
mediated and non-immune-mediated neuropathies of different 
etiologies and compared data with disease controls and among 
neuropathy subgroups. We showed that neuropathies lead to an 
enlargement of lower extremity nerves, in general, and that the 
superficial peroneal nerve LD may be a useful parameter indicat-
ing immune-mediated, and particularly, vasculitic neuropathies.
Our study is one of the few examining nerves of the lower 
extremities in patients with polyneuropathies of different eti-
ologies. In the majority of studies, upper limb nerves have been 
assessed due to easier access. However, peripheral neuropathies 
typically affect lower extremities first and more severely; thus, 
systematic HRUS investigation of lower limb nerves is essential 
and increasingly performed (13, 14).
The CSA is regarded as the most precise and reproducible 
parameter in HRUS (24) and is therefore reported in the major-
ity of studies. When comparing our mean values of nerve CSA 
with previously published data from other laboratories, we see 
discrepancies. For instance, mean CSA of the proximal sural 
nerve was reported as 5.3 mm2 (25, 26) or 3.6 mm2 (27, 28) in 
healthy controls by other groups; this is much larger than our 
mean value of 1.7 mm2 and that reported in recent studies (12, 
14). For the proximal part of the sural nerve, the mean CSA as 
reported by Hobson-Webb et al. (5.2 mm2) was also larger than 
in our study (1.9  mm2) (26). Similarly, our mean CSA results 
for the distal tibial nerve were smaller than in previous studies 
(9, 28–32) but comparable with recent data (12, 14). In patients 
with vasculitic neuropathy, Ito et  al. reported a mean CSA for 
the sural nerve of 4.9 ± 0.5 mm2, which is larger than our data 
(2.0 ± 1.7 mm2) and for the tibial nerve of 13.5 ± 3.7 mm2 (30), 
which is much larger than the 3.5 ± 0.9 mm2 found in our study. 
For the common peroneal nerve, published CSA data are again 
larger than those determined in our study. Published values range 
between 11.2 ±  3.3 and 16.1 mm2 (26, 31–35), whereas in our 
study, mean CSA was 4.1 ± 2.3 mm2, which is again similar with 
data in more recent studies (12, 14).
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There are several potential reasons for these discrepancies. 
Major issues are the performance of the ultrasonography devices 
used and the methodology of measurements. It is of note that, in 
early studies, less powerful devices with 5–12 MHz transducers 
were used (33), in contrast to the currently available 15–18 MHz 
transducers. Moreover, the device itself together with the Tissue 
Harmonic Imaging algorithm influences the delineation of 
bordering lines. Also, the manually performed measurements 
are investigator dependent and a potential source of discrepancy, 
particularly when using the zoom function (23). Another aspect 
is the exact site of measurement, which is different between 
studies. Thus, the comparison of HRUS data across studies is 
only possible if the measurements are performed under identical 
conditions. It is also desirable that every sonography laboratory 
establishes its own normative values (9).
Nerve biopsy is the gold standard for the diagnosis of vascu-
litic neuropathy (4, 36). The sural nerve, the superficial radial 
nerve, and the superficial peroneal nerve are potential candidates 
for diagnostic biopsy in peripheral neuropathies. The reported 
diagnostic yield of a sural nerve biopsy alone in vasculitic neu-
ropathy varies between 20 and 60% (5). Some studies emphasized 
a higher diagnostic value of the superficial peroneal nerve (4, 
37), particularly in combination with the peroneal brevis muscle 
(38), whereas other studies reported no superiority of a combined 
nerve/muscle biopsy (39, 40). So far, no HRUS data had been 
published for the deep and superficial peroneal nerve in periph-
eral neuropathies. In our study, the superficial peroneal nerve 
LD distinguished best between immune-mediated, particularly, 
vasculitic, neuropathies, and controls.
Our study gives evidence that peripheral nerve LD may be 
informative when assessing immune-mediated neuropathies. 
This parameter distinguished best between the subgroups inves-
tigated here and was more reliable than the CSA (24, 41). There 
are also studies showing that the CSA of a peripheral nerve is 
equally informative as the LD (42–44). However, when investigat-
ing the peroneal nerve, the CSA may not be the ideal parameter. 
Practically, it is almost impossible to achieve a perfect transversal 
image of the peroneal nerve when it twists around the fibular 
caput; at such sites the nerve will be visualized more accurately 
in the longitudinal plane.
In recent publications, scores combining clinical, electro-
physiological, and ultrasonography items were used (45, 46). 
These score approaches may become valuable additions to single 
nerve ultrasonography parameters; however, they need to be 
confirmed in studies with large patient cohorts before routine 
application.
Our study has several limitations. The study cohort was small 
and particularly the study subgroups consisted of <10 patients 
each. The control group was not investigated with nerve conduc-
tion studies to fully exclude a potential subclinical neuropathy. 
We did not investigate all nerves bilaterally and due to the 
potential asymmetric phenotype of peripheral neuropathies, 
may have missed the most pathological areas of the respective 
nerves. As in any sonography, the results very much depend on 
the investigator’s experience. Kristina A. Schäfer was trained and 
supervised accordingly (by Wolfgang Müllges and Mira Schließer); 
additionally, all data were confirmed off-line by a second exam-
iner (Wolfgang Müllges). However, data were not reproduced by 
a third fully independent investigator. Some measurement sites 
are also areas prone to entrapment syndromes. However, none of 
the study subjects had clinical signs of nerve entrapment. We also 
did not control for the body mass index, for which controversial 
data are available with regard to influence on the HRUS measure-
ments (9, 47). All patients were Caucasian adults of 160–180 cm 
in height; thus, data correction for ethnicity and height was not 
necessary (48). It is also to be noted that there was a large range of 
disease duration in the patient group, which may have an impact 
on study results.
The major strength of our study is, first, that diagnostic sural 
nerve biopsy was performed in all patients, confirming vasculitic 
neuropathy in a subgroup and allowing the comparison of nerve 
histology and sonography. This has hardly ever been done in prior 
studies. Second, we investigated lower extremity nerves, which 
should be much more informative in patients with neuropathies 
than nerves of the upper limbs.
The lack of standardization of measurements is a major 
drawback in current nerve sonography applications. For clinical 
practice, it is also essential that every sonography unit should 
establish at-site normative values that are obtained under stand-
ardized conditions. Here, we used defined points of transducer 
positioning. Our study shows that it is well possible to system-
atically depict the morphology of lower leg peripheral nerves by 
HRUS. Large scale studies with clinically, neurophysiologically, 
and histologically well characterized patient cohorts are war-
ranted and eventually supplemented by nerve MRI.
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